

References

L-32

1. National Institute for Health and Care Excellence. Point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease. 2017.
2. Diagnosing and Managing IBD. Crohn's & Colitis Foundation of America. 2017.
3. Hayes, Inc. Hayes Health Technology Brief. *Fecal calprotectin assay for monitoring disease activity in Crohn's Disease*. Lansdale, PA: Hayes, Inc.; 07/07/2017.
4. Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG Clinical Guideline: Management of Crohn's disease in adults. *Am J Gastroenterol*. 2018;113(4):481-517.
5. National Institute for Health and Care Excellence (NICE). Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel DG11. 2013 [Reaffirmed 2017].
6. Heida A, Park KT, van Rheenen PF. Clinical utility of fecal calprotectin monitoring in asymptomatic patients with inflammatory bowel disease: A systematic review and practical guide. *Inflamm Bowel Dis*. 2017;23(6):894-902.
7. Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn's disease (CALM): A multicentre, randomised, controlled phase 3 trial. 2018;390(10114):2779-2789.
8. Rokkas T, Portincasa P, Kourouvakis IE. Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: A diagnostic accuracy meta-analysis. *J Gastrointestin Live Dis*. 2018;27(3):299-306.
9. Emile S, Gilshtein H, Wexner S. Outcome of ileal pouch anal anastomosis in patients with indeterminate colitis: A systematic review and meta-analysis. *J Crohns Colitis*; 30;14(7):1010-1020.
10. Petryszyn P, Staniak A, Wolosianska A, Ekk-Cierniakowski P. Faecal calprotectin as a diagnostic marker of inflammatory bowel disease in patients with gastrointestinal symptoms: Meta-analysis. *Eur J Gastroenterol Hepatol*. 2019;31(11):1306-1312.
11. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, et al. ACG clinical guideline: Management of Crohn's disease in adults. *Am J Gastroenterol*. 2018;113(4):481-517.

12. El-Matary W, Abej E, Deora V, Singh H, et al. Impact of fecal calprotectin measurement on decision-making in children with inflammatory bowel disease. *Front Pediatr.* 2017;5:7.
13. Ananthakrishnan AN, Nguyen GC, Bernstein CN. AGA clinical practice update on management of inflammatory bowel disease in elderly patients: Expert review. *Gastroenterology.* 2021; 160(1):445-451.
14. Lacy BE, Pimentel M, Brenner DM, et al. ACG clinical guideline: Management of irritable bowel syndrome. *Am J Gastroenterol.* 2021; 116(1):17-44.
15. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD. *Gastroenterology.* 2021; 160(5):1570-1583.
16. Ricciuto A, Griffiths AM. Clinical value of fecal calprotectin. *Crit Rev Clin Lab Sci.* 2019;56(5):307-320.
17. D'Amico F, Rubin DT, Kotze PG, et al. International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. *United European Gastroenterol J.* 2021;9(4):451-460.